ARCHIVES

Markison leaving Bristol-Myers, two others promoted in reorganization.

This article is from The Cancer Letter archive.

Vol. 30 No. 05 | January 30, 2004

Download PDF Visit The Full Archive

Related Articles

Blincyto Demonstrates Response In Minimal Residual Disease ALL

December 26, 2014

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

October 22, 2004

NCCN Admits Two New Member Institutions

March 22, 2013

Low Dose DFMO Reduces Colon Adenoma Recurrence

April 25, 2008

Q & A With Shannon Brownlee: Task Force Independence at Stake In Debate over PSA Screening

October 6, 2011

NCI Funds New Centers At Stanford, Baylor.

June 15, 2007